GSK Adjusts Vaccine Sales Forecast as Q3 Holds Steady, Analysts See Potential

Highlights:

• Vaccine Sales Fall Short: Arexvy and Shingrix sales missed forecasts, leading to a second downgrade in GSK’s vaccine segment.
• Overall Growth Maintained: Revenues rose by 2% to £8 billion, with core EPS up 5% at 49.7p, driven by specialty medicines.
• Analysts See Value Potential: Despite vaccine concerns, Shore Capital views GSK as a promising long-term growth play with a fair value estimate of 2,200p.

GSK PLC (LSE:GSK) reported its third-quarter earnings, revealing mixed results as underperformance in its vaccine franchise weighed on an otherwise steady performance. While the company posted a 2% increase in revenue, reaching £8 billion, and a 5% rise in core EPS to 49.7p, sales of its RSV vaccine Arexvy and Shingles treatment Shingrix missed market expectations. The sales miss led to a second downgrade for GSK’s vaccine division this year, overshadowing positive gains in its specialty medicines segment and successful product launches in oncology and HIV.

In response, GSK’s share price fell nearly 3% to 1,411p in early trading, reflecting investor concerns over the vaccine division’s outlook. Despite the vaccine challenges, GSK maintained its full-year guidance, aiming to deliver revenue growth of 7-9% and EPS growth of 10-12%, with performance expected to settle near the midpoint of this range.

Vaccine Franchise Struggles with Sales Misses

The third-quarter sales figures for GSK’s vaccine franchise were below analyst expectations, highlighting challenges in one of the company’s key segments. Arexvy, GSK’s RSV vaccine, generated £188 million in sales, while Shingrix, the company’s leading shingles vaccine, brought in £739 million. Both results fell short of forecasts, leading to a further downgrade in the vaccine division’s growth outlook. Analysts have expressed concern over GSK’s vaccine sales trajectory, as prescription data hinted at potential underperformance prior to the earnings release.

The weak vaccine sales contrast with GSK’s strong performance in other therapeutic areas, raising questions about the franchise’s growth potential amid an increasingly competitive landscape in the vaccine market. CEO Emma Walmsley acknowledged the shortfall but noted that robust growth in specialty medicines, as well as new launches in oncology and HIV treatments, helped offset the decline in vaccine sales.

Specialty Medicines Offset Vaccine Weakness

GSK’s specialty medicines segment demonstrated resilience in the third quarter, providing a solid counterbalance to the vaccine division’s struggles. Strong growth in oncology and HIV products underscored the company’s diversified portfolio and its ability to leverage new product launches to support overall performance. This segment’s growth is part of GSK’s strategic focus on high-value medicines that address unmet medical needs, with specialty treatments playing a critical role in driving the company’s medium- to long-term growth objectives.

CEO Emma Walmsley emphasized GSK’s commitment to research and development, noting that the quarter marked “further good progress” in its pipeline. The company’s investments in specialty areas such as oncology and HIV align with its strategy to build a resilient portfolio that can withstand fluctuations in other divisions, such as vaccines. This balance between specialty medicines and vaccines reflects GSK’s ability to adapt its business model and product offerings to meet changing market demands.

Analysts Highlight Value Potential Amid Vaccine Concerns

While the vaccine division’s performance may be underwhelming, some analysts see GSK as a promising long-term value play. Shore Capital’s early analysis highlighted GSK’s attractive valuation, particularly in light of the Zantac litigation being resolved. With potential liabilities no longer hanging over the company, Shore Capital believes the market may be undervaluing GSK’s near-term growth prospects and its ability to achieve longer-term goals.

Shore Capital estimates a fair value of 2,200p for GSK’s stock, noting that it trades at a forward price-earnings multiple of just over eight times. The investment firm views GSK’s current valuation as modest given its growth potential, particularly as the company continues to focus on expanding its specialty medicines portfolio and enhancing its R&D pipeline. According to ShoreCap, the vaccine segment’s underperformance is more of a side issue, and GSK’s overall trajectory remains promising.

Maintaining Full-Year Guidance and Strategic Outlook

Despite the challenges in its vaccine segment, GSK has maintained its full-year guidance, expecting revenue growth to settle in the 7-9% range and core EPS to grow by 10-12%. This stability reflects the company’s commitment to long-term growth while balancing short-term headwinds. Walmsley noted that GSK’s strong results in specialty medicines and its new product launches highlight the resilience the company has built within its portfolio.

GSK’s approach to managing its diverse product lines, alongside its R&D investments, positions it well to capitalize on emerging opportunities in healthcare. The company’s focus on high-growth therapeutic areas and the prioritization of its specialty portfolio underscore its strategy to deliver steady growth while navigating market challenges.

Market Reaction and Future Prospects

Following the earnings release, GSK’s stock dropped nearly 3% to 1,411p, reflecting investor concerns over the vaccine sales miss. However, the company’s focus on a balanced product portfolio and consistent R&D investments suggests that it remains well-positioned for sustained growth. With Shore Capital emphasizing GSK’s undervaluation, the long-term outlook for the company appears strong, especially as it continues to leverage its specialty medicines and expand into oncology and HIV markets.

Looking forward, GSK’s ability to navigate the competitive vaccine market, address prescription challenges, and drive new product growth will be central to its success. The company’s commitment to long-term strategic objectives and its balanced approach to growth provide a stable foundation for future performance, positioning GSK as a key player in the global pharmaceutical landscape.

Conclusion: Navigating Short-Term Hurdles with Long-Term Vision

GSK’s third-quarter performance highlights the mixed dynamics of a diversified healthcare portfolio, where growth in specialty medicines has helped offset challenges in the vaccine segment. The underperformance of Arexvy and Shingrix may weigh on short-term sentiment, but the company’s commitment to R&D, specialty product growth, and a balanced portfolio underpins its long-term growth strategy.

Analysts like Shore Capital see GSK’s valuation as a promising opportunity, with the company’s forward-looking strategy and strong specialty medicine performance providing a foundation for future growth. As GSK continues to navigate the competitive landscape and adapt its offerings, the company’s focus on high-value treatments and market resilience positions it for continued success in the years ahead.